Risperidone When administered concomitantly with topiramate at escalating doses of 100, 250, and 400 mg/day, there was a reduction in risperidone systemic exposure (16% and 33% for steady-state AUC at the 250 and 400 mg/day doses of topiramate)
Cell Metab 29:10031011.e4 Romero R, Sayin VI, Davidson SM, Bauer MR, Singh SX, LeBoeuf SE, Karakousi TR, Ellis DC, Bhutkar A, Snchez-Rivera FJ, Subbaraj L, Martinez B, Bronson RT, Prigge JR, Schmidt EE, Thomas CJ, Goparaju C, Davies A, Dolgalev I, Heguy A, Allaj V, Poirier JT, Moreira AL, Rudin CM, Pass HI, Vander Heiden MG, Jacks T, Papagiannakopoulos T (2017) Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis
This suggests that manipulation of PTMs in these peripheral enzymes may offer an indirect yet potent strategy to modulate the ferroptosis-suppressive function of the MBOAT1/2-MUFA axis
Studies were not excluded based on their risk of bias rating, but results from those with higher risk should be interpreted with caution